

BIOCRYST PHARMACEUTICALS INC

Form 8-K/A

December 22, 2005

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K/A  
Amendment No. 1  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of Report: November 30, 2005  
BioCryst Pharmaceuticals, Inc.  
(Exact Name of Registrant as Specified in Charter )**

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-23186**  
(Commission  
File Number)

**62-1413174**  
(IRS Employer  
Identification #)

**2190 Parkway Lake Drive, Birmingham, Alabama 35244**  
(Address of Principal Executive Office)  
**(205) 444-4600**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Explanatory Note: This Form 8-K/A amends the Form 8-K filed by BioCryst Pharmaceuticals, Inc. on November 30, 2005 (file no. 000-23186) (the "Form 8-K").

**TABLE OF CONTENTS**

Item 1.01 Entry Into A Material Definitive Agreement

Item 9.01. Exhibits

SIGNATURES

EXHIBIT INDEX

Development and License Agreement

---

**Table of Contents**

**Item 1.01 Entry Into A Material Definitive Agreement.**

As disclosed in the Form 8-K, on November 30, 2005, BioCryst Pharmaceuticals, Inc. (the Company ) announced that it entered into a Development and License Agreement dated as of November 29, 2005 (the Roche Agreement ), with F.Hoffmann-La Roche Ltd and Hoffman-La Roche Inc. (collectively Roche ). The Roche Agreement is a collaboration between the Company and Roche for development of the Company s clinical compound BCX-4208 for transplantation and autoimmune diseases.

The Form 8-K included a description of the material terms of the Roche Agreement. A redacted copy of the Roche Agreement is attached as Exhibit 10.2 to this Form 8-K/A and incorporated herein by reference.

**Item 9.01. Exhibits.**

**Exhibit No.**

**Description**

- |      |   |
|------|---|
| 10.2 | Development and License Agreement dated as of November 29, 2005, by and between BioCryst Pharmaceuticals, Inc. and F.Hoffmann-La Roche Ltd and Hoffman-La Roche Inc. (Portions omitted pursuant to request for confidential treatment.) |
|------|---|

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 22, 2005

BioCryst Pharmaceuticals, Inc.

By: /s/ Michael A. Darwin

Michael A. Darwin  
Chief Financial Officer and Chief  
Accounting Officer

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
10.2	Development and License Agreement dated as of November 29, 2005, by and between BioCryst Pharmaceuticals, Inc. and F.Hoffmann-La Roche Ltd and Hoffman-La Roche Inc. (Portions omitted pursuant to request for confidential treatment.)